Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV.7m8.CaMeRaOpsin Gtx Optogenetics
- Development stage
- Preclinical
- Lead developer
- Adverum Biotechnologies
- Modality
- Gene Therapies
- Administration
- Intravitreal
01
Overview
AAV.7m8.CaMeRaOpsin Gtx Optogenetics is an investigational intravitreal gene therapy being developed for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Developed by Adverum Biotechnologies (which agreed to be acquired by Eli Lilly in late 2025), the therapy utilizes Adverum's proprietary AAV.7m8 vector capsid to deliver a transgene encoding CaMeRaOpsin, an engineered melanopsin mutant. This optogenetic approach is designed to restore vision in patients with advanced photoreceptor loss by expressing the light-sensitive melanopsin mutant in surviving inner retinal cells, effectively turning them into functional photoreceptors. The program is currently in preclinical development.
- Other names
- CaMeRaOpsinCaMeRaOpsin GTxCaMeRaOpsin Program for Optogenetics
02
Targets
Chimeric optogenetic opsinGq/11 (Guanine nucleotide-binding protein subunit alpha-q/11)11-cis-Retinal
Beyond the preview
Go deeper on AAV.7m8.CaMeRaOpsin Gtx Optogenetics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV.7m8.CaMeRaOpsin Gtx Optogenetics.